N-acetyltransferase-2 and medical history in bladder cancer cases with a suspected occupational disease (BK 1301) in Germany

Journal of Toxicology and Environmental Health - Part A: Current Issues

Volumn 71, Issue 13-14, 2008, Pages 906-910

  Weistenhöfer, Wobbeke ^a,b   Blaszkewicz, Meinolf ^a   Bolt, Hermann M ^a   Golka, Klaus ^a  

^a LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE; AZO DYE; BENZIDINE; CARCINOGEN;

ACETYLATION; ACETYLATOR PHENOTYPE; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RISK; CHEMICAL INDUSTRY; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GERMANY; HUMAN; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NONMEDICAL OCCUPATIONS; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; PAINTER; PARAMETER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SECOND CANCER; VARNISHER;

ADULT; AGED; AGED, 80 AND OVER; AMINES; ARYLAMINE N-ACETYLTRANSFERASE; CARCINOGENS; ENVIRONMENTAL POLLUTANTS; GENETIC PREDISPOSITION TO DISEASE; GERMANY; HUMANS; MIDDLE AGED; OCCUPATIONAL EXPOSURE; POLYMERASE CHAIN REACTION; SMOKING; URINARY BLADDER NEOPLASMS;

EID: 47349128668     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287390801988681     Document Type: Article

References (25)

1. Blaszkewicz, M. 2004. N-Acetyltransferase 2 (phenotyping: caffeine test). In Analyses of hazardous substances in biological materials, eds. J. Angerer and M. Müller, Vol. 9, Special issue: Marker of susceptibility, pp. 165-182. Weinheim: Wiley-VCH.
2. Blaszkewicz, M., Dannappel, D., Thier, R., and Lewalter, J. 2004. N-Acetyltransferase 2 (genotyping). In Analyses of hazardous substances in biological materials, eds. J. Angerer and M. Müller, Vol. 9, Special issue: Marker of susceptibility, pp. 135-163. Weinheim: Wiley-VCH.
3. Bolt, H. M., and Golka, K. 1993. Zur früheren Exposition von Malern gegenüber Azofarbmitteln. Arbmed. Sozialmed. Umweltmed. 10:417-421.
4. Carcinogenic Potency Project. 2007. The carcinogenic potency database. www.potency.berkeley.edu/chemicalsummary.html
5. Cartwright, R. A., Rogers, H. J., Barham-Hall, D., Glashan, R. W., Ahmad, R. A., Higgins, E., and Kahn, M. A. 1982. Role of N-acetyltransferase in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer. Lancet 2:842-846.
6. Cascorbi, I., Brockmöller, J., Mrozikiewicz, P. M., Bauer, S., Loddenkemper, R., and Roots, I. 1996. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res. 56:3961-3966.
7. Colditz, G., DeJong, W., Hunter, D., Trichopoulos, D., and Willet, W., eds. 1996. Harvard report on cancer prevention, Vol. 1: Causes of human cancer. Cancer Causes Control. 7(Suppl.):3-59.
8. DFG Deutsche Forschungsgemeinschaft, ed. 2006. Maximum concentrations and biological tolerance values at the workplace. Weinheim: Wiley-VCH Verlag. List of MAK und BAT Values 2006 (Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area Report No. 42).
9. Doll, R., and Peto, R. 1981. The causes of cancer: Quantitative estimates of avoidable risks of cancer in the United States today. J. Natl. Cancer Inst. 66:1191-1308.
10. Gaber, K., Harreus, U. A., Matthias, C., Kleinsasser, N. H., and Richter, E. 2007. Hemoglobin adducts of the human bladder carcinogen o-toluidine after treatment with the local anesthetic prilocaine. Toxicology 229:157-164.
11. Garcia-Closas, M., Malats, N., Silverman, D., Dosemeci, M., Kogevinas, M., Hein, D. W., Tardon, A., Serra, C., Carrato, A., Garcia-Closas, R., Lloreta, J., Castano-Vinyals, G., Yeager, M., Welch, R., Chanock, S., Chatterjee, N., Wacholder, S., Samanic, C., Tora, M., Fernandez, F., Real, F. X., and Rothman, N. 2005. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: Results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366:649-659.
12. GEKID Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (Association of Population-Based Cancer Registries in Germany) in cooperation with the Robert Koch Institut. 2006. Cancer in Germany Incidence and Trends. Fifth revised, updated edition Saarbrüken, pp. 68-71. http:// www.ekr.med.uni-erlangen.de/GEKID/Doc/kid2006_english.pdf
13. Gold, L. S., Manley, N. B., Slone, T. H., and Ward, J. M. 2001. Compendium of chemical carcinogens by target organ: Results of chronic bioassays in rats, mice, hamsters, dogs, and monkeys. Toxicol. Pathol. 29:639-652.
14. Golka, K., Kopps, S., and Myslak, Z. W. 2004. Carcinogenicity of azo colorants: Influence of solubility and bioavailability. Toxicol. Lett. 151:203-210.
15. Golka, K., Prior, V., Blaszkewicz, M., and Bolt, H. M. 2002. The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: A review considering ethnic differences. Toxicol. Lett. 128: 229-241.
16. Golka, K., Prior, V., Blaszkewicz, M., Cascorbi, I., Schöps, W., Kierfeld, G., Roots, I., and Bolt, H. M. 1996. Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany. Scand. J. Work Environ. Health 22:332-328.
17. Grant, D. M., Tang, B. K., and Kalow, W. 1983. Polymorphic N-acetylation of caffeine metabolite. Clin. Pharmacol. Ther. 33:355-359.
18. HVBG Hauptverband der gewerblichen Berufsgenossenschaften, Hrsg. 2005. Beruflich verursachte Krebserkrankungen, eine Darstellung der im Zeitraum 1978 bis 2003 anerkannten Berufskrankheiten, HVBG, 8., überarbeitete und ergänzte Auflage, Sankt Augustin.
19. Hein, D. W., Grant, D. M., Sim, E., Minchin R. F., and Boukouvala, S. 2007. Human NAT2 alleles. Revised December 6, 2007. www.louisville.edu/ medschool/pharmacology/NAT2.html
20. Lang, N. P., and Kadlubar, F. F. 1991. Aromatic and heterocyclic amine metabolism and phenotyping in humans. Prog. Clin. Biol. Res. 372:33-47.
21. Lewalter, J., and Miksche, L. W. 1992. Empfehlungen zur arbeitsmedizinischen Prävention expositions- und dispositionsbedingter Arbeitsstoff-Beanspruchungen. Verh. Dtsch. Ges. Arbeitsmed. 31:135-139.
22. Morinaga, K., Oshima, A., and Hara, I. 1982. Multiple primary cancers following exposure to benzidine and beta-naphthylamine. Am. J. Ind. Med. 3:243-246.
23. Popp, W., Ohndorf, U., Stommel, P., Vahrenholz, C., and Norpoth, K. 1993. Primäre Mehrfachtumoren nach Einwirkung aromatischer Amine. Arbeitsmed. Sozialmed. Umweltmed. 28:183-190.
24. Sabbioni, G., and Richter, E. 1999. Aromatic amines, nitroarenes, and heterocyclic aromatic amines. In Toxicology, eds. H. Marquardt, S. G. Schäfer, R. McClellan, and F. Welsch, pp. 729-741. San Diego: Academic Press.
25. Schöps, W., Prior, V., Golka, K., Blaszkewicz, M., Cascorbi, I., Roots, I., Bolt, H. M., and Kierfeld, G. 1997. Untersuchung zur klinischen Relevanz der Acetyliererphänotypisierung bei 196 Urotheltumorpatienten. Urologe A 36:64-67.